Hepatic steatosis-insulin resistance and type 2 diabetes in people with HIV at diagnosis: effect of initial antiretroviral therapy.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
15 Nov 2024
15 Nov 2024
Historique:
received:
10
04
2024
accepted:
31
08
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
ppublish
Résumé
We evaluated the impact of hepatic steatosis-insulin resistance (HS-IR) and liver fibrosis (LF) on type 2 diabetes mellitus (DM2) using triglyceride-glucose (TyG) and Fibrosis-4 (FIB-4). The incidence of DM2 was 12.9 [95% confidence interval (CI), 16.9-9.7] and 9.8 (95% CI, 6.9-13.6) per 1000 person-years in HS-IR and LF. The prevalence of HS-IR was significantly lower at 12 and 24 months with TDF + (3TC or FTC) + RPV [hazard ratio (HR) 0.5 [95% CI, 0.3-0.8], P < 0.01 at 12 months; 0.6 [0.4-0.9], P = 0.01 at 24 months].
Identifiants
pubmed: 39474653
doi: 10.1097/QAD.0000000000004008
pii: 00002030-202411150-00015
doi:
Substances chimiques
Anti-Retroviral Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1982-1987Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Sarkar S, Brown TT. Diabetes in people with HIV. Curr Diab Rep 2021; 21:13.
Sudipa Sarkar TTB. DM in PLWHIV. Curr Diab Rep 2022; 21:1–13.
Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2 diabetes and its impact on the immune system. Curr Diabetes Rev 2020; 16:442–449.
Gutiérrez-Fisac JL, Guallar-Castillón P, León-Muñoz LM, Graciani A, Banegas JR, Rodríguez-Artalejo F. Prevalence of general and abdominal obesity in the adult population of Spain, 2008–2010: the ENRICA study. Obes Rev 2012; 13:388–392.
Monroe AK, Glesby MJ, Brown TT. Diagnosing and managing diabetes in HIV-infected patients: current concepts. Clin Infect Dis 2015; 60:453–462.
Busca C, Sánchez-Conde M, Rico M, Rosas M, Valencia E, Moreno A, et al. Assessment of noninvasive markers of steatosis and liver fibrosis in human immunodeficiency virus-monoinfected patients on stable antiretroviral regimens. Open Forum Infect Dis 2022; 9:ofac279.
Ma H, Liang W, Han A, Zhang Q, Gong S, Bai Y, et al. Ambient particulate matter and renal function decline in people with HIV/AIDS patients. AIDS 2024; 38:713–721.
Caeran G, de Almeida LL, Ilha TASH, de Carvalho JAM, Stein C, Moresco RN, et al. Insulin resistance and its association with osteoporosis in people living with HIV. J Endocr Soc 2022; 6:bvac148.
Sterling RK, King WC, Khalili M, Kleiner DE, Hinerman AS, Sulkowski M, et al. Performance of serum-based scores for identification of mild hepatic steatosis in HBV mono-infected and HBV-HIV co-infected adults. Dig Dis Sci 2022; 67:676–688.
Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317–1325.
Shah AG, Smith PG, Sterling RK. Comparison of FIB-4 and APRI in HIV-HCV coinfected patients with normal and elevated ALT. Dig Dis Sci 2011; 56:3038–3044.
Wong VWS, Vergniol J, Wong GLH, Foucher J, Chan HLY, Le Bail B, et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010; 51:454–462.
Lemoine M, Assoumou L, De Wit S, Girard PM, Valantin MA, Katlama C, et al. Diagnostic accuracy of noninvasive markers of steatosis, NASH, and liver fibrosis in HIV-monoinfected individuals at risk of nonalcoholic fatty liver disease (NAFLD): results from the ECHAM study. J Acquir Immune Defic Synd 2019; 80:e86–e94.
Sebastiani G, Milic J, Gioe C, Al Hinai AS, Cervo A, Lebouche B, et al. Diagnosis of liver fibrosis in ageing patients with HIV at risk for nonalcoholic fatty liver disease in Italy and Canada: assessment of a two-tier pathway. Lancet HIV 2022; 9: (Suppl 1): S4.